{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:58:45Z","timestamp":1760014725890,"version":"3.40.5"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.bpobgyn.2018.06.010","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T15:41:39Z","timestamp":1530200499000},"page":"49-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Conservative management of reproductive cancers. Ovarian protection during treatment"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5077-6814","authenticated-orcid":false,"given":"Wanyuan","family":"Cui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly-Anne","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bpobgyn.2018.06.010_bib1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.5491\/SHAW.2012.3.3.166","article-title":"Malignant Tumours of the female reproductive system","volume":"3","author":"Weiderpass","year":"2012","journal-title":"Saf Health Work"},{"key":"10.1016\/j.bpobgyn.2018.06.010_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"year":"2018","series-title":"SEER cancer Statistics","author":"National Cancer Institute","key":"10.1016\/j.bpobgyn.2018.06.010_bib3"},{"year":"2018","series-title":"SEER cancer stat facts: cervical cancer","author":"National Cancer Institute","key":"10.1016\/j.bpobgyn.2018.06.010_bib4"},{"year":"2018","series-title":"SEER cancer stat facts: uterine cancer","author":"National Cancer Institute","key":"10.1016\/j.bpobgyn.2018.06.010_bib5"},{"year":"2018","series-title":"SEER cancer stat facts: ovarian cancer","author":"National Cancer Institute","key":"10.1016\/j.bpobgyn.2018.06.010_bib6"},{"issue":"1","key":"10.1016\/j.bpobgyn.2018.06.010_bib7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12957-017-1222-4","article-title":"Oncofertility in patients with stage I epithelial ovarian cancer: fertility-sparing surgery in young women of reproductive age","volume":"15","author":"Jiang","year":"2017","journal-title":"World J Surg Oncol"},{"issue":"9","key":"10.1016\/j.bpobgyn.2018.06.010_bib8","first-page":"1","article-title":"Fertility-sparing management in cervical cancer: balancing oncologic outcomes with reproductive success","volume":"3","author":"Willows","year":"2016","journal-title":"Gynaecol Oncol Res Prac"},{"issue":"6","key":"10.1016\/j.bpobgyn.2018.06.010_bib9","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(16)30032-8","article-title":"Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review","volume":"17","author":"Bentivegna","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.bpobgyn.2018.06.010_bib10","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1093\/annonc\/mdw311","article-title":"Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues","volume":"27","author":"Bentivenga","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.bpobgyn.2018.06.010_bib11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.rbmo.2018.03.018","article-title":"Survival of selected patients with ovarian cancer treated with fertility-sparing surgery","volume":"37","author":"Hedback","year":"2018","journal-title":"Reprod Biomed Online"},{"issue":"1","key":"10.1016\/j.bpobgyn.2018.06.010_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/gyno.2002.6805","article-title":"Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy","volume":"87","author":"Schilder","year":"2002","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.bpobgyn.2018.06.010_bib13","first-page":"149","article-title":"Systematic comparison of radical vaginal trachelectomy and radical hysterectomy in the treatment of early-stage cervical cancer","volume":"112","author":"Han","year":"2010","journal-title":"Obstet Gynaecol"},{"key":"10.1016\/j.bpobgyn.2018.06.010_bib14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000350797","article-title":"Fertility-sparing surgery for young women with early-stage epithelial ovarian cancer","volume":"76","author":"Nam","year":"2013","journal-title":"Gynecol Obstet Invest"},{"issue":"2","key":"10.1016\/j.bpobgyn.2018.06.010_bib15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ygyno.2008.07.014","article-title":"Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma","volume":"111","author":"Diaz","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.bpobgyn.2018.06.010_bib16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/IGC.0b013e3182370f51","article-title":"Fertility-sparing surgery for early cervical cancer-approach to less radical surgery","volume":"22","author":"Raju","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.bpobgyn.2018.06.010_bib17","first-page":"36","article-title":"Fertility preservation in patients with cancer: ASCO clinical practice guideline update","author":"Oktay","year":"2018","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.bpobgyn.2018.06.010_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djj243","article-title":"Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study","volume":"98","author":"Sklar","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.bpobgyn.2018.06.010_bib19","doi-asserted-by":"crossref","first-page":"252.e1","DOI":"10.1016\/j.ajog.2013.11.014","article-title":"Impaired steroidogenesis and apoptosis of granulosa-luteal cells in primary culture induced by cis-platinum","volume":"210","author":"Chatterjee","year":"2014","journal-title":"Am J Obstetr Gynaecol"},{"issue":"3","key":"10.1016\/j.bpobgyn.2018.06.010_bib20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002800050482","article-title":"The formation and persistence of carboplatin-DNA adducts in rats","volume":"38","author":"Blommaert","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"10.1016\/j.bpobgyn.2018.06.010_bib21","doi-asserted-by":"crossref","first-page":"e1688","DOI":"10.1073\/pnas.1620729114","article-title":"AMH\/MIS as contraceptive that protects the ovarian reserve during chemotherapy","volume":"114","author":"Kano","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.bpobgyn.2018.06.010_bib22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1006\/gyno.1994.1221","article-title":"Menstrual and hormone patterns in women treated with high dose cisplatin and bleomycin","volume":"54","author":"Maneschi","year":"1994","journal-title":"Gynaecol Oncol"},{"issue":"10","key":"10.1016\/j.bpobgyn.2018.06.010_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(06)70869-5","article-title":"Survival patterns after oophorectomy in premenopausal women: a population based cohort study","volume":"7","author":"Rocca","year":"2006","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.bpobgyn.2018.06.010_bib24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/pon.4502","article-title":"A systematic review of patient oncofertility support needs in reproductive cancer patients aged 14 to 45 years of age","volume":"27","author":"Logan","year":"2017","journal-title":"Psycho Oncol"},{"issue":"5","key":"10.1016\/j.bpobgyn.2018.06.010_bib25","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/jnci\/djr541","article-title":"Quality of life, fertility concerns, and behavioural health outcomes in younger breast cancer survivors: a systematic review","volume":"104","author":"Howard-Anderson","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.bpobgyn.2018.06.010_bib26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000433590","article-title":"14th St. Gallen international breast cancer conference 2015: evidence, controversies, consensus - primary therapy of early breast cancer: opinions expressed by German experts","volume":"10","author":"Jackisch","year":"2015","journal-title":"Breast Care"},{"year":"2017","series-title":"NCCN clinical practice guidelines in Oncology","author":"NCCN","key":"10.1016\/j.bpobgyn.2018.06.010_bib27"},{"issue":"1","key":"10.1016\/j.bpobgyn.2018.06.010_bib28","doi-asserted-by":"crossref","first-page":"e8772","DOI":"10.1371\/journal.pone.0008772","article-title":"Human ovarian reserve from conception to the menopause","volume":"5","author":"Wallace","year":"2010","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.bpobgyn.2018.06.010_bib29","doi-asserted-by":"crossref","DOI":"10.1093\/humupd\/dmu019","article-title":"Prevention of chemotherapy induced ovarian damage: possible roles for hormonal and non hormonal attenuating agents","volume":"20","author":"Roness","year":"2014","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.bpobgyn.2018.06.010_bib30","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1200\/JCO.2012.42.8185","article-title":"Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial","author":"Demeestere","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2018.06.010_bib31","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.fertnstert.2013.03.014","article-title":"Antimullerian hormone, the assessment of ovarian reserve, and the reproductive outcome of the young women with cancer","volume":"99","author":"Anderson","year":"2013","journal-title":"Fertil Steril"},{"issue":"5","key":"10.1016\/j.bpobgyn.2018.06.010_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdp394","article-title":"Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study","volume":"21","author":"Mar Fan","year":"2010","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.bpobgyn.2018.06.010_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2001.19.14.3306","article-title":"Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer","volume":"19","author":"Shapiro","year":"2001","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.bpobgyn.2018.06.010_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/1471-0528.12828","article-title":"Impact of a premature menopause on cognitive function in later life","volume":"121","author":"Ryan","year":"2014","journal-title":"BJOG"},{"issue":"suppl 6","key":"10.1016\/j.bpobgyn.2018.06.010_bib35","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/annonc\/mdt199","article-title":"Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Peccatori","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bpobgyn.2018.06.010_bib36","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMra1614676","article-title":"Fertility preservation in women","volume":"377","author":"Donnez","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpobgyn.2018.06.010_bib37","first-page":"139","article-title":"Oocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence of the development of global guidance","volume":"23","author":"Rienzi","year":"2016","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.bpobgyn.2018.06.010_bib38","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S0140-6736(14)60834-5","article-title":"Fertility preservation in women with cancer","volume":"384","author":"De Vos","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.bpobgyn.2018.06.010_bib39","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1470-2045(14)70334-1","article-title":"Fertility preservation for girls and young women with cancer: population-based validation of criteria for ovarian tissue cryopreservation","volume":"15","author":"Wallace","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.bpobgyn.2018.06.010_bib40","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood-2010-01-265751","article-title":"Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukaemia is potentially unsafe","volume":"116","author":"Dolmans","year":"2010","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.bpobgyn.2018.06.010_bib41","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1001\/jama.2015.17291","article-title":"Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial","volume":"314","author":"Lambertini","year":"2015","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.bpobgyn.2018.06.010_bib42","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1056\/NEJMoa1413204","article-title":"Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy","volume":"372","author":"Moore","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.bpobgyn.2018.06.010_bib43","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/annonc\/mdx184","article-title":"GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial","volume":"28","author":"Leonard","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.bpobgyn.2018.06.010_bib44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamaoncol.2015.3251","article-title":"Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early stage breast cancer: a systematic review and meta-analysis","volume":"2","author":"Munhoz","year":"2016","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.bpobgyn.2018.06.010_bib45","doi-asserted-by":"crossref","DOI":"10.1210\/er.2003-0002","article-title":"Gonadotropin-releasing hormone receptors","volume":"25","author":"Millar","year":"2004","journal-title":"Endocr Rev"},{"issue":"2","key":"10.1016\/j.bpobgyn.2018.06.010_bib46","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2265.1987.tb00779.x","article-title":"Suppression of ovarian activity by zoladex depot (ICI 118630), a long acting luteinizing hormone releasing hormone agonist analogue","volume":"26","author":"West","year":"1987","journal-title":"Clin Endocrinol"},{"issue":"3","key":"10.1016\/j.bpobgyn.2018.06.010_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2012.08.017","article-title":"DNA damage-induced primordial follicle oocyte apoptosis and loss of fertility require TAp63-mediated induction of Puma and Noxa","volume":"48","author":"Kerr","year":"2012","journal-title":"Mol Cell"},{"issue":"2","key":"10.1016\/j.bpobgyn.2018.06.010_bib48","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1095\/biolreprod52.2.365","article-title":"Luteinizing hormone- releasing hormone agonist inhibits cyclophosphamide induced ovarian follicular depletion in Rhesus monkeys","volume":"52","author":"Ataya","year":"1995","journal-title":"Biol Reprod"},{"issue":"3","key":"10.1016\/j.bpobgyn.2018.06.010_bib49","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2011.991","article-title":"Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial","volume":"306","author":"Del Mastro","year":"2011","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.bpobgyn.2018.06.010_bib50","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1200\/JCO.2015.65.8864","article-title":"No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial","volume":"34","author":"Demeestere","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bpobgyn.2018.06.010_bib51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/10245330600954072","article-title":"Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD)","volume":"12","author":"Giuseppe","year":"2007","journal-title":"Hematology"},{"key":"10.1016\/j.bpobgyn.2018.06.010_bib52","first-page":"90","article-title":"Protocol combining GnRH agonists and GnRH antagonists for rapid suppression and prevention of gonadal damage during cytotoxic therapy","volume":"25","author":"Mardesic","year":"2004","journal-title":"Eur J Gynaecol Oncol"},{"issue":"1","key":"10.1016\/j.bpobgyn.2018.06.010_bib53","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.fertnstert.2010.08.053","article-title":"Combination of gonadotropin-releasing hormone (GnRH) agonists with GnRH antagonists before chemotherapy reduce but does not completely prevent a follicle-stimulating hormone flare-up","volume":"95","author":"von Wolff","year":"2011","journal-title":"Fertil Steril"},{"issue":"9","key":"10.1016\/j.bpobgyn.2018.06.010_bib54","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1177\/1933719116682876","article-title":"A combination of GnRH antagonist and agonist for fertility preservation in adolescent female murine model","volume":"24","author":"Knudtson","year":"2017","journal-title":"Reprod Sci"},{"issue":"6","key":"10.1016\/j.bpobgyn.2018.06.010_bib55","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/humrep\/deh257","article-title":"The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice","volume":"19","author":"Meirow","year":"2004","journal-title":"Hum Reprod"},{"issue":"2","key":"10.1016\/j.bpobgyn.2018.06.010_bib56","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ygyno.2008.09.044","article-title":"The GnRH antagonist reduces chemotherapy-induced ovarian damage in rats by suppressing the apoptosis","volume":"112","author":"Huang","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"51","key":"10.1016\/j.bpobgyn.2018.06.010_bib57","first-page":"1","article-title":"Assessment of fertility protection and ovarian reserve with GnRH antagonist in rats undergoing chemotherapy with cyclophosphamide","volume":"8","author":"Lemos","year":"2010","journal-title":"Reprod Biol Endocrinol"},{"issue":"16","key":"10.1016\/j.bpobgyn.2018.06.010_bib58","first-page":"1","article-title":"Combination of a GnRH agonist with an antagonist prevents flare-up effects and protects primordial ovarian follicles in the rat ovary from cisplatin-induced toxicity: a controlled experimental animal study","volume":"11","author":"Li","year":"2013","journal-title":"Reprod Biol Endocrinol"},{"issue":"5","key":"10.1016\/j.bpobgyn.2018.06.010_bib59","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/09513590701327661","article-title":"Protection of ovarian function and fertility using a combination of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist during cancer treatment in young females","volume":"23","author":"Potolog-Nahari","year":"2007","journal-title":"Gynecol Endocrinol"},{"issue":"5","key":"10.1016\/j.bpobgyn.2018.06.010_bib60","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1479-828X.2011.01346.x","article-title":"A pilot study to assess the use of gonadotrophin antagonist cetrorelix in preserving ovarian function during chemotherapy","volume":"51","author":"Whitehead","year":"2011","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.bpobgyn.2018.06.010_bib61","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.0858","article-title":"Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient\u2013level data","author":"Lambertini","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bpobgyn.2018.06.010_bib62","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s12032-013-0667-8","article-title":"Effect of leuprolide acetate on ovarian function after cyclophosphamide\u2013doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial","volume":"30","author":"Song","year":"2013","journal-title":"Med Oncol"},{"issue":"1","key":"10.1016\/j.bpobgyn.2018.06.010_bib63","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/AOG.0b013e31827374e2","article-title":"Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial","volume":"121","author":"Elgindy","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.bpobgyn.2018.06.010_bib64","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1200\/JCO.2011.34.6890","article-title":"Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer","volume":"30","author":"Munster","year":"2012","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.bpobgyn.2018.06.010_bib65","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1200\/JCO.2010.32.5704","article-title":"Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study","volume":"29","author":"Gerber","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bpobgyn.2018.06.010_bib66","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.fertnstert.2007.12.044","article-title":"Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study","volume":"91","author":"Badawy","year":"2009","journal-title":"Fertil Steril"}],"container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693418301299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693418301299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,16]],"date-time":"2019-02-16T07:39:16Z","timestamp":1550302756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693418301299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":66,"alternative-id":["S1521693418301299"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2018.06.010","relation":{},"ISSN":["1521-6934"],"issn-type":[{"type":"print","value":"1521-6934"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conservative management of reproductive cancers. Ovarian protection during treatment","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Obstetrics & Gynaecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2018.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}